Sanofi Aventis eyeing Genzyme

Reports Friday surfaced that Sanofi Aventis is looking to acquire Genzyme as it faces stiff competition from generic drugs. By acquiring Genzyme, it would be their first step into the generics and biosimilars market.

According to the article:
[Genzyme's] research pipeline includes candidates for genetic diseases like Duchenne and Becker muscular dystrophy, Niemann-Pick type B, and Parkinson disease. It also has drugs in development for cardiometabolic, renal, transplant, and immune diseases, as well as hematologic oncology.

Source: Genetic Engineering & Biotechnology News

Share this article with your social network, just click below to share now!

Share |